FDAnews
www.fdanews.com/articles/196775-nice-backs-bayers-vitrakvi-for-nhs-use

NICE Backs Bayer’s Vitrakvi for NHS Use

April 23, 2020

The UK’s National Institute for Health and Care Excellence (NICE) has recommended Bayer’s Vitrakvi (larotrectinib) for use by the National Health Service for treatment of neurotrophic tyrosine receptor kinase (NTRK) fusion-positive solid tumors.

NICE said that the results from trials suggest that NTRK gene fusions shrink in response to larotrectinib but that it’s not clear how well the drug works compared with other treatments.

The institute originally recommended against the drug last month, finding that it was not cost-effective at the price.

View today's stories